Changes in soluble PD-L1 levels in patients with advanced non-small cell lung cancer

Changes in soluble PD-L1 levels in patients with advanced non-small cell lung cancer

Soluble programmed death-1 ligand (sPD-L1) in the serum of non-small cell lung cancer (NSCLC) patients is a crucial factor in disease prognosis and an indicator for immunotherapy response. This study aimed to evaluate changes in sPD-L1 levels in advanced NSCLC patients. Between May 2018 and October...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ta Thang Ba, Pham Nhung Thi Kim, Nguyen Dung Tien, Tran Tien Viet, Tran Cuong Tan, Cong Luong Thuc, Vu Hoan Ngoc, Le Hien Thi Dieu, Dao Bang Ngoc
Format:	Article
Language:	English
Published:	Sciendo 2024-11-01
Series:	Forum of Clinical Oncology
Subjects:	soluble pd-l1 (spd-l1) membrane pd-l1 (mpd-l1) non-small cell lung cancer (nsclc)
Online Access:	https://doi.org/10.2478/fco-2023-0036
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer
by: Vesna Ćeriman Krstić, et al.
Published: (2025-01-01)

Assessing the Clinical Relevance of Soluble PD-1 and PD-L1: A Multi-Cohort Study Across Diverse Tumor Types and Prognostic Implications
by: Nikolay E. Kushlinskii, et al.
Published: (2025-02-01)

The Prognostic Value of Serum Soluble Programmed Death 1 (sPD‐1) and Programmed Death Ligand 1 (sPD‐L1) in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis About Cohort Studies
by: Qiyao Yu, et al.
Published: (2024-11-01)

Expression and its clinical significance of sPD-1 and sPD-L1 in patients with primary nephrotic syndrome
by: LV Zhi-an, et al.
Published: (2020-01-01)

B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer
by: Yang Zhang, et al.
Published: (2025-05-01)

Immunotherapy as an Innovative Treatment for Non-Small Cell Lung Cancer – A Comprehensive Literature Review
by: Aneta Rasińska, et al.
Published: (2025-05-01)

PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
by: Ryohei Kondo, et al.
Published: (2025-05-01)

Soluble programmed cell death ligand-1 as a predictive biomarker for severity and poor prognosis in pulmonary tuberculosis
by: Xiaojue Wang, et al.
Published: (2025-12-01)

Synthesis and Evaluation of [<sup>18</sup>F]AlF-NOTA-iPD-L1 as a Potential Theranostic Pair for [<sup>177</sup>Lu]Lu-DOTA-iPD-L1
by: Guillermina Ferro-Flores, et al.
Published: (2025-07-01)

The predictive value of total body PET/CT in high PD-L1 expression and immunotherapy in advanced non-small cell lung cancer patients
by: Huibin Jin, et al.
Published: (2025-07-01)

Investigating the correlation between IDO1/PD-L1 expression or co-expression and EGFR/KRAS gene mutations in advanced NSCLC
by: Zhidong Yin, et al.
Published: (2025-08-01)

Association between PD-L1 expression with EGFR, ALK, and ROS1 driver oncogene mutations in non-small cell lung cancer
by: Dülger Onur, et al.
Published: (2025-01-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status
by: David Dora, et al.
Published: (2023-12-01)

Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors
by: Green Hong, et al.
Published: (2025-04-01)

Serum soluble PD‐1 plays a role in predicting infection complications in patients with acute pancreatitis
by: Xingxing Yu, et al.
Published: (2021-03-01)

Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study
by: Alessandro Inno, et al.
Published: (2025-07-01)

IRF4 Mediates Immune Evasion to Facilitate EBV Transformation
by: Ling Wang, et al.
Published: (2025-06-01)

Can the co-localization of CD8+, PD-1, PD-L1 AND PD-L2 patterns provide guidance in clinical evolution of patients with head and neck cutaneous squamous cell carcinoma?
by: Gustavo Nunes Bento, et al.
Published: (2025-09-01)

The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer
by: Qian Zhu, et al.
Published: (2025-04-01)

Expression patterns of estrogen and androgen receptors in NSCLC patients according to the PD-L1 profile
by: Vianey Rodriguez-Lara, et al.
Published: (2025-06-01)

Temporal Effect on PD‐L1 Detection and Novel Insights Into Its Clinical Implications in Non–Small Cell Lung Cancer
by: Gopal P. Pathak, et al.
Published: (2024-10-01)

Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
by: Armando Santoro, et al.
Published: (2024-10-01)

Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with non-small cell lung cancer in China
by: LI Yuan, GUO Lingchuan, YUAN Yong, ZHENG Qiang, JIN Yan, MING Jian
Published: (2025-02-01)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
by: Otgontuya Ganbaatar, et al.
Published: (2021-12-01)

Modern possibilities of using immunotherapy in the treatment of cervical cancer
by: A. V. Tarasova, et al.
Published: (2021-09-01)

Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends
by: Talaiti Tuergan, et al.
Published: (2025-12-01)

LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy
by: Camil Ciprian Mireștean, et al.
Published: (2025-04-01)

Efficacy and safety outcomes of PD-1/PD-L1 inhibitors in recurrent cholangiocarcinoma: a real-world, multicenter and retrospective study
by: Lihui Lin, et al.
Published: (2025-07-01)

Evaluation of polymorphism in BCL-2, PD-1, and PD-L1 genes in myelodysplastic neoplasms
by: Bartłomiej Kuszczak, et al.
Published: (2025-01-01)

The immune exhaustion paradox: activated functionality during chronic bacterial infections
by: María L Ruiz-de la Cruz, et al.
Published: (2024-12-01)

Enhancing cancer care with improved checkpoint inhibitors
by: Vickram A S, et al.
Published: (2024-10-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty
by: Meshach Asare-Werehene, et al.
Published: (2025-07-01)

Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment
by: A. Yu. Kalinchuk, et al.
Published: (2024-03-01)

Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1
by: Barry D. Hock, et al.
Published: (2025-05-01)

Clinical characteristics, outcomes, and predictive modeling of patients diagnosed with immune checkpoint inhibitor therapy-related pneumonitis
by: Antonious Hazim, et al.
Published: (2025-05-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
by: Amjad Zafar, et al.
Published: (2024-11-01)

The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade
by: Przemysław Bielski, et al.
Published: (2025-05-01)

Distinct characteristics of BTLA/HVEM axis expression on Tregs and its impact on the expansion and attributes of Tregs in patients with active pulmonary tuberculosis
by: Peijun Tang, et al.
Published: (2024-09-01)